Eiger BioPharmaceuticals, Inc.
EIGR
Clasificación en acciones
#36382
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Precio por acción
$1.73
Última sincronización: 2025-06-17
Capitalización bursátil
$2.55M
Cambio (1 día)
-0.29%
Cambio (1 año)
-79.71%
País
US
Comercio Eiger BioPharmaceuticals, Inc. (EIGR)
Categoría
Healthcare
Ingresos de Eiger BioPharmaceuticals, Inc. (EIGR)
Ingresos en Dec 2023 TTM: $15.77M
Según los últimos informes financieros de Eiger BioPharmaceuticals, Inc., los ingresos actuales de la empresa (TTM) son $15.77M. En 2022, la empresa obtuvo unos ingresos de $13.48M un aumento con respecto a los ingresos del año 2021, que fueron de $12.14M. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Eiger BioPharmaceuticals, Inc. desde 2016 hasta 2026
Ingresos al final de cada año
| Año | Ingresos | Cambiar |
|---|---|---|
| 2026 (TTM) | $15.77M | 0.00% |
| 2023 | $15.77M | 16.98% |
| 2022 | $13.48M | 11.05% |
| 2021 | $12.14M | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
Ingresos de empresas similares o competidoras
| Empresa | Ingresos | Diferencia de ingresos | País |
|---|---|---|---|
| $12.62B | 79,937.41% |
US
|
|
| $2.23B | 14,025.40% |
US
|
|
| $15.74B | 99,718.22% |
AU
|
|
| $6.02B | 38,074.65% |
NL
|
|
| $10.11B | 64,001.86% |
BE
|
